Lipoprotein glomerulopathy (LPG) is a rare inherited disease caused by mutations in the APOE gene, encoding apolipoprotein E (apoE). Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by overactivation of the alternative complement pathway. Here we report the case of a 21-year-old man with LPG who developed aHUS. A functional complement assay demonstrated an overactivation of the complement system. Complementary genetic analysis revealed a homozygous aHUS risk allele for complement factor-H related 1 (CFHR1), CFHR1∗B. To the best of our knowledge, this is the first report of an aHUS in a patient with LPG.

Keywords: case report, lipoprotein glomerulopathy, thrombotic microangiopathy, atypical hemolytic uremic syndrome, nephrotic syndrome, apolipoprotein E, complement factor-H related 1

INTRODUCTION

Lipoprotein glomerulopathy (LPG) is a rare inherited renal disease caused by mutations in the APOE gene, encoding apolipoprotein E (apoE) (1). Approximately 200 LPG cases have been reported worldwide, the majority in Asian populations (2). LPG is an autosomal dominant disorder with incomplete penetrance (1, 3). Gene analysis discovered various mutations of APOE. Most of them are missense variants close to the LDL receptor binding site. However, mutants far from the binding site and mutants involving deletion of several amino acids are also reported (4). The clinical manifestation and histological findings seem to be common with different APOE variants (1). A kidney biopsy is essential for LPG diagnosis (3). Pathognomonic histologic features include glomerular capillary lipid thrombi without significant infiltration by foamy macrophages (5, 6). Clinically the disease manifests with proteinuria or nephrotic syndrome, and may gradually progress to chronic renal failure (1).

Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by overactivation of the alternative complement pathway (7). Complement factor H (CFH) is the primary inhibitor of this pathway (Figure 2A). The complement factor H-related (CFHR) gene family encodes a group of plasma proteins genetically and structurally related to CFH. The risk allele CFHR1∗B (Figure 2B), resulting from a gene conversion event between CFH and CFHR1, is strongly associated with aHUS. In this report, we present a case of LPG with aHUS.
CASE DESCRIPTION

A 21-year-old Swiss-Indonesian man was referred to our nephrology clinic in June 2019. He had end-stage renal disease with a creatinine value of 907 µmol/l (Table 1). Previously, at the age of 14 years, an asymptomatic, increased blood pressure of 158/102 mmHg was discovered during a school-based examination, and he was investigated at the children's hospital of Lucerne, Switzerland. His medical history revealed swollen eyelids in the morning for the last 3 years. Clinical examination was regular except for bilateral ankle edema. Further workup identified a nephrotic syndrome with a protein to creatinine ratio of 586 mg/mmol, a serum albumin concentration of 27 g/L, total cholesterol of 9.5 mmol/l (Table 1), and microhematuria with 30% dysmorphic erythrocytes. Screening for hepatitis B and C was negative, and autoantibodies (antinuclear antibodies, anti dsDNA antibodies, antineutrophil cytoplasmic antibodies, and antiglomerular basement membrane antibodies) were negative.

Echocardiography showed mild left ventricular hypertrophy. The renal biopsy established the diagnosis of LPG. It showed glomerular capillary dilatations with lipoprotein thrombi with lamella formation (Figure 1A). No fibrin thrombi, fragmented erythrocytes or fibrinoid necrosis suggestive of aHUS was seen. Chronic changes in the form of secondary focal segmental scleroses and mild interstitial fibrosis with tubular atrophy were already present. By immunohistochemistry, mild to moderate unspecific depositions of IgM and C5b-9 within the glomeruli were detected. IgA, IgG, and C3c were negative within the glomeruli. Transmission electron microscopy showed the characteristic concentrically layered and vacuolated lipoprotein thrombi (Figure 1B). Analysis of APOE revealed E3/E3 genotype. Sequencing of the APOE gene detected a heterozygous 9-bp deletion in exon 4 (NM_000041.3: c.480_488del (p.Leu162_Lys164del, traditional nomenclature: 142_144del)), resulting in a 3-amino acid deletion in a region involved in receptor binding of the apo E molecule and previously associated with LPG (10, 11). In the literature, this mutation is often named APOE Tokyo/Maebashi (1). A grandfather of the patient in Indonesia received a kidney transplant at the age of about 60 years. Otherwise, the family history brought to light no renal disease in either of the patient’s parents. The patient has no siblings. Therapy was started with an ACE-inhibitor (enalapril 10 mg/d) and a lipid-lowering agent (atorvastatin 20 mg/d). As the patient emigrated to Indonesia soon after the diagnosis, medical follow-up was lost.

In June 2019, after his return to Switzerland, he complained about fatigue, epigastric pain, and a dizzy sensation.

### Table 1 | Laboratory values.

|                       | At diagnosis of LPG 2012 | At admission 2019 | 8-days after | 12-days after |
|-----------------------|-------------------------|------------------|--------------|--------------|
| **Blood**             |                         |                  |              |              |
| **Hematology**        |                         |                  |              |              |
| Hemoglobin (140–180 g/L) | 127 g/L                | 84 g/L           | 77 g/L       | 63 g/L       |
| Fragmentocytes        | NA                      | neg.             | neg.         | pos.         |
| Platelet count (150–350 × 10⁹/L) | 374 × 10⁹/L          | 114 × 10⁹/L      | 43 × 10⁹/L   | 51 × 10⁹/L   |
| **Chemistry**         |                         |                  |              |              |
| Potassium (3.5–5.1 mmol/L) | 3.69 mmol/L             | 5.49 mmol/L      | 4.92 mmol/L  | 4.83 mmol/L  |
| Phosphate (0.87–1.45 mmol/L) | 1.42 mmol/L             | 2.24 mmol/L      | 1.97 mmol/L  | 2.41 mmol/L  |
| Creatinine (62–106 µmol/L)   | 71 µmol/L         | 907 µmol/L       | 1,006 µmol/L | 985 µmol/L   |
| Urea (<8.3 mmol/L)     | 5.6 mmol/L              | 31.7 mmol/L      | 29.6 mmol/L  | 32.3 mmol/L  |
| LDH (135–225 U/L)      | 4 µmol/L                | 5.0 µmol/L       | 7.1 µmol/L   | NA           |
| Haptoglobin (0.3–2.0 g/L) | NA                    | 0.47 g/L         | <0.1 g/L     | NA           |
| Total bilirubin (<21.0 µmol/L) | 27 g/L                | NA               | 43 g/L       | 42 g/L       |
| Albumin                | 9.52 mmol/L             | NA               | 2.9 mmol/L   | NA           |
| Total cholesterol (<5 mmol/L) | 1.47 mmol/L             | NA               | 1.3 mmol/L   | NA           |
| Cholesterol-HDL (>1 mmol/L) | 7.57 mmol/L             | NA               | 1.4 mmol/L   | NA           |
| Cholesterol-LDL        | 1.63 mmol/L             | NA               | 1.6 mmol/L   | NA           |
| Triglyceride (<2 mmol/L) | 1.05 g/L                | 0.81 g/L         | 0.74 g/L     | NA           |
| Complement and ADAMTS-13 | 0.19 g/L               | 0.20 g/L         | 0.21 g/L     | NA           |
| ADAMTS-13 activity     | NA                      | NA               | 100%         |              |
| **Urine**             |                         |                  |              |              |
| Prot/Creat ratio (<11.3 mg/mmol) | 586 mg/mmol       | 230 mg/mmol      | NA           | NA           |
*NA, non-available.
FIGURE 1 | Glomerulus with intraglomerular lipoprotein thrombi. (A) Glomerulus with dilated glomerular capillaries containing characteristic acellular, lamellated, intracapillary lipoprotein thrombi. PAS staining. (B) Dilated peripheral glomerular capillary containing a lipoprotein thrombus with its characteristic electron microscopic appearance. While the endothelial cells on the left-hand side are visible and slightly enlarged, they are not detectable in the upper right side. Transmission electron microscopy.
FIGURE 2 | Complement activation cascade. Factor H and factor H related (FHR) 1 allotypes. (A) The complement system has three pathways (8). The classical pathway (CP) is triggered by antibody-antigen complexes interacting with C1q. The lectin pathway (LC) is triggered when lectins, e.g., mannose binding lectin (MBL), bind carbohydrates on surfaces. Both pathways lead to cleavage of C4 and C2, enabling the assembly of the C3 convertase C4b2a. The alternative pathway (AP) is constitutively active at low levels due to the spontaneous transformation of C3 to C3(H2O). This product is functionally C3b-like and allows the formation of the fluid phase C3 convertase C3(H2O)Bb. The latter cleaves C3 and enables the formation of the cell surface alternative pathway C3 convertase C3bBb. Factor H, the master regulator of the AP, interferes with this pathway at multiple levels (red). Assembly of the C5 convertases C4b2a3b and C3bBb3b initiates the last phase of the complement cascade, which is identical for all three pathways. (B) CFHR1 encoding FHR1 is a member of the factor H gene family. FHR1 comprises five short consensus repeats (SCRs) with different degrees of identity with homologous domains of factor H. The allotype CFHR1*B is associated with an increased risk for aHUS if present in homozygosity. FHR1*B harbors the amino acids Tyr at position 157, Val at 159, and Gln at 173 in SCR3, which are identical to those in SCR 18 of factor H (9). (C) Factor H is composed of 20 SCR domains arranged like beads on a string. On cell surfaces, factor H induces dissociation of surface-bound C3bBb and inactivation of C3b. The high sequence similarity of FHR1*B to factor H may lead to a competition between factor H and FHR1*B, a consecutive decrease of the functional activity of factor H and thus predisposing to aHUS (9).

pressure was 171/106 mmHg. No edema was noticed. In contrast to the findings 7 years earlier, the lipid profile was normal. The laboratory results showed progressive thrombocytopenia and coombs-negative hemolytic anemia with fragmentocytes (Table 1), and the diagnosis of thrombotic microangiopathy (TMA) was made. At this time, C3 levels were reduced. ADAMTS13 activity was 100% (Table 1). We started dialysis in July 2019, shortly after his first emergency consultation in our clinic. Due to a paracentral scotoma (left > right) fundoscopic exam was performed, which showed hypertensive retinopathy. A magnetic resonance imaging (MRI) of the brain was normal. A detailed, further analysis of the complement system revealed a functional complement defect (Table 2) and the presence of a homozygous aHUS risk allele for CFHR1, CFHR1*B (Table 3). Factor H antibodies were negative. Currently, the patient is listed for renal transplantation. We plan to treat the patient with the C5 inhibitor eculizumab during the first 3–6 months after transplantation. Close monitoring of the complement activity, i.e., CH50 test and C3 levels, will be required. Also, protocol biopsies will help us to detected aHUS and LPG recurrence at an early stage. Depending on posttransplant lipid levels and the results of protocol biopsies, we plan to treat the patient with fibrates as their use can induce clinical remission in some patients with LPG (3).

DISCUSSION

We present a case of a young, swiss-indonesian man with LPG. The initial manifestation was hypertension and nephrotic...
The accumulation of homocysteine may trigger endothelial injury and TMA/aHUS (c.2671G>TMA/aHUS). Dyslipidemia was no more present when the patient returned to Switzerland, and he was off lipid-lowering therapy. This suggests that the severe nephrotic syndrome at the initial presentation contributed to the altered lipid profile. Our patient may belong to a subgroup of individuals with LPG and dyslipidemia, which manifests only under specific circumstances. Furthermore, over the course of the disease, the patient developed TMA. In the literature, we found only one TMA report in a patient with LPG, attributed to malignant hypertension. Hypertension may have contributed to TMA in our patient as well. However, the reduced C3 levels suggest an overactivation of the alternative complement pathway as an underlying mechanism. This is further supported by the findings of an ex vivo assay with the patient’s serum, which evoked increased binding of the terminal complement complex C5b-9 to resting and activated human endothelial cells (Table 3). Complementary, genetic analyses of the complement system found homozygosity for CFHR1*B (Figure 2B), a finding strongly associated with aHUS. A gene conversion event between the CFHR1 and CFB genes resulted in CFHR1*B, and functionally CFHR1*B is thought to compete with the complement regulatory factor H on cell surfaces (9) (Figure 2C). Interestingly, patients deficient in CFHR1 and CFHR3 have an increased risk for aHUS also. Their susceptibility is associated with factor H antibodies (9), which in turn may be due to modulation of B cell activation (20).

We do not know what triggered aHUS in this patient and to which extent aHUS accelerated renal function decline. However, we obtained a laboratory result from Indonesia showing thrombocytopenia 2 months before the patient returned to Switzerland. This indicates that aHUS may have contributed to the renal damage over a prolonged period.

Potentially, the APOE gene mutations associated with LPG may facilitate aHUS in a patient at risk, as apoE structural deformities caused by APOE mutations facilitate aggregation of apoE. These aggregates may not only directly contribute to the onset of LPG (4) but to the onset of aHUS also. As our patient’s renal biopsy did not show any signs of TMA, the postulated apoE aggregates alone seem to be insufficient to trigger aHUS in this case. The lack of TMA signs in the renal biopsy (Figures 1A, B) makes it also unlikely that TMA triggered the onset of LPG. Additional factors such as hypertension and, further, unknown risk factors must have contributed to this patient’s disease course.

**CONCLUSION**

To the best of our knowledge, this is the first report of aHUS in a patient with LPG with a documented dysfunction of the complement system and an associated genetic risk factor.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.
ETHICS STATEMENT

Written informed consent from the patient has been obtained for the publication of any identifiable data.

AUTHOR CONTRIBUTIONS

AJ initiated the case study, the APOE sequencing, the detailed analysis of the complement system, and draw Figure 2. LK collected all data. LK and AJ wrote the manuscript. JS performed sequencing of APOE, analyzed the data, and reviewed the manuscript. PH-M helped with the preanalytical handling of blood samples for the complement analysis and reviewed the manuscript. EB was involved in the complement analysis and reviewed the manuscript. TN was responsible for the patient's initial workup leading to the diagnosis of LPG and reviewed the manuscript. All authors read and approved the submitted version of the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.679048/full#supplementary-material